WO2001034135A3 - Combinaisons oncolytiques pour traitement des cancers - Google Patents

Combinaisons oncolytiques pour traitement des cancers Download PDF

Info

Publication number
WO2001034135A3
WO2001034135A3 PCT/US2000/030944 US0030944W WO0134135A3 WO 2001034135 A3 WO2001034135 A3 WO 2001034135A3 US 0030944 W US0030944 W US 0030944W WO 0134135 A3 WO0134135 A3 WO 0134135A3
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
treatment
combinations
oncolytic
oncolytic combinations
Prior art date
Application number
PCT/US2000/030944
Other languages
English (en)
Other versions
WO2001034135A2 (fr
Inventor
Jerome Herbert Fleisch
Jason Scott Sawyer
Beverly Ann Teicher
Douglas Wade Beight
Edward C R Smith
William Thomas Mcmillen
Original Assignee
Lilly Co Eli
Jerome Herbert Fleisch
Jason Scott Sawyer
Beverly Ann Teicher
Douglas Wade Beight
Edward C R Smith
William Thomas Mcmillen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Jerome Herbert Fleisch, Jason Scott Sawyer, Beverly Ann Teicher, Douglas Wade Beight, Edward C R Smith, William Thomas Mcmillen filed Critical Lilly Co Eli
Priority to AU20418/01A priority Critical patent/AU2041801A/en
Priority to JP2001536135A priority patent/JP2003513914A/ja
Priority to EP00983695A priority patent/EP1231939A2/fr
Priority to CA002390789A priority patent/CA2390789A1/fr
Publication of WO2001034135A2 publication Critical patent/WO2001034135A2/fr
Publication of WO2001034135A3 publication Critical patent/WO2001034135A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Furan Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyrane Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne les combinaisons thérapeutiques d'inhibiteurs de leucotriène (LTB4) et d'agents anticancéreux. L'invention concerne également un traitement anticancéreux comprenant l'administration conjointe d'inhibiteurs du leucotriène (LTB4) et d'agents anticancéreux.
PCT/US2000/030944 1999-11-11 2000-11-09 Combinaisons oncolytiques pour traitement des cancers WO2001034135A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU20418/01A AU2041801A (en) 1999-11-11 2000-11-09 Oncolytic combinations for the treatment of cancer
JP2001536135A JP2003513914A (ja) 1999-11-11 2000-11-09 癌の処置のための腫瘍崩壊薬の組み合わせ
EP00983695A EP1231939A2 (fr) 1999-11-11 2000-11-09 Combinaisons oncolytiques pour traitement des cancers
CA002390789A CA2390789A1 (fr) 1999-11-11 2000-11-09 Combinaisons oncolytiques pour traitement des cancers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16471399P 1999-11-11 1999-11-11
US60/164,713 1999-11-11

Publications (2)

Publication Number Publication Date
WO2001034135A2 WO2001034135A2 (fr) 2001-05-17
WO2001034135A3 true WO2001034135A3 (fr) 2002-03-21

Family

ID=22595757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030944 WO2001034135A2 (fr) 1999-11-11 2000-11-09 Combinaisons oncolytiques pour traitement des cancers

Country Status (5)

Country Link
EP (1) EP1231939A2 (fr)
JP (1) JP2003513914A (fr)
AU (1) AU2041801A (fr)
CA (1) CA2390789A1 (fr)
WO (1) WO2001034135A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001034197A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques aux fins du traitement de cancer
WO2001034198A2 (fr) * 1999-11-11 2001-05-17 Eli Lilly And Company Combinaisons oncolytiques pour traitement des cancers
JP2001247459A (ja) 2000-03-03 2001-09-11 Oakland Uniservices Ltd 癌の組み合わせ療法
CA2408622A1 (fr) * 2000-05-09 2001-11-15 Creighton University Procedes servant a inhiber la proliferation et a induire l'apoptose dans des cellules cancereuses
JP2004505047A (ja) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド 複合治療による癌治療
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
AU2007307597A1 (en) 2006-10-12 2008-04-17 Institute Of Medicinal Molecular Design. Inc. Carboxylic acid derivatives
US8633245B2 (en) 2008-04-11 2014-01-21 Institute Of Medicinal Molecular Design, Inc. PAI-1 inhibitor
BR112014016450A2 (pt) 2012-01-10 2019-09-24 Lilly Co Eli composto antagonista de leucotrieno b4

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140709A2 (fr) * 1983-10-31 1985-05-08 Merck Frosst Canada Inc. Inhibiteurs de la 5-lipoxigénase
US4704400A (en) * 1986-06-24 1987-11-03 Merck & Co., Inc. Medicarpin derivatives and analogs
EP0617032A1 (fr) * 1993-03-23 1994-09-28 J. URIACH & CIA. S.A. Dérivés de cyanomethylpyridine comme antagonistes du PAF et inhibiteurs de 5-lipoxygénase
WO1998047890A1 (fr) * 1997-04-21 1998-10-29 G.D. Searle & Co. Derives de benzopyrannes substitues pour le traitement de l'inflammation

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0140709A2 (fr) * 1983-10-31 1985-05-08 Merck Frosst Canada Inc. Inhibiteurs de la 5-lipoxigénase
US4704400A (en) * 1986-06-24 1987-11-03 Merck & Co., Inc. Medicarpin derivatives and analogs
EP0617032A1 (fr) * 1993-03-23 1994-09-28 J. URIACH & CIA. S.A. Dérivés de cyanomethylpyridine comme antagonistes du PAF et inhibiteurs de 5-lipoxygénase
WO1998047890A1 (fr) * 1997-04-21 1998-10-29 G.D. Searle & Co. Derives de benzopyrannes substitues pour le traitement de l'inflammation

Also Published As

Publication number Publication date
AU2041801A (en) 2001-06-06
WO2001034135A2 (fr) 2001-05-17
CA2390789A1 (fr) 2001-05-17
EP1231939A2 (fr) 2002-08-21
JP2003513914A (ja) 2003-04-15

Similar Documents

Publication Publication Date Title
AU4564200A (en) Method for treating cancer using camptothecin derivatives and 5-fluorouracil
AU9208498A (en) Novel apparatus and method of treating a tumor in the extremity of a patient
AU6012900A (en) Apparatus and method for treating body tissues with electricity or medicaments
WO2002005799A3 (fr) Composes vasomodulateurs et inhibiteurs selectifs de la cyclo-oxygenase-2 pour le traitement des douleurs generalisees et des cephalees
HUS1500001I1 (hu) ET743 alkalmazása kombinációs terápiában dexametazollal rákbetegség kezelésére
AU2001276039A1 (en) Methods and apparatus for brachytherapy treatment of prostate disease
AU7094800A (en) Methods and apparatus for treating body tissues and bodily fluid vessels
AU2072201A (en) Agents and methods for the treatment of proliferative diseases
AU3021001A (en) Thiazolidine carboxylic acid derivatives and their use in the treatment of cancer
MY136037A (en) Biphenyl pyrimidone lp-pla2 inhibitors
AU2495200A (en) Compositions and methods for the treatment of tumor
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003200731A1 (en) Compositions and methods for the treatment of tumor
WO2001028494A3 (fr) Derives nordihydroguaiartiques destines a une utilisation dans le traitement de tumeurs
PL352330A1 (en) Derivatives of pyridopyranoazepine, making of same and use of same in therapy
WO2001034135A3 (fr) Combinaisons oncolytiques pour traitement des cancers
AU5838700A (en) Method for treating and preventing finger disorders
WO2001034133A3 (fr) Combinaisons oncolytiques pour traitement des cancers
WO2001034197A3 (fr) Combinaisons oncolytiques aux fins du traitement de cancer
WO2002087503A3 (fr) Compositions et methodes de traitement des polypes colorectaux et du cancer colorectal
AU7856100A (en) Methods for treating solid tumors with irradiation and bacteria
WO2001034199A3 (fr) Combinaisons oncolytiques pour le traitement du cancer
AU5672000A (en) Method for detecting the effect of different chemotherapeutic agents and/or radiation therapy in malignant diseases and method for selecting more effective therapeutic agents for the therapy thereof
AU2625700A (en) Method and apparatus for treatment of tissues with fluid jets

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 518405

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 20418/01

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 536135

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2390789

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000983695

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10110673

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2000983695

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000983695

Country of ref document: EP